Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitus.
Ashraf GM, Greig NH, Khan TA, Hassan I, Tabrez S, Shakil S, Sheikh IA, Zaidi SK, Akram M, Jabir NR, Firoz CK, Naeem A, Alhazza IM, Damanhouri GA, Kamal MA.
CNS Neurol Disord Drug Targets. 2014;13(7):1280-93.
Similar articles
Linking Alzheimer's disease and type 2 diabetes mellitus via aberrant insulin signaling and inflammation.
Kamal MA, Priyamvada S, Anbazhagan AN, Jabir NR, Tabrez S, Greig NH.
CNS Neurol Disord Drug Targets. 2014 Mar;13(2):338-46. Review.
Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.
Mushtaq G, Greig NH, Khan JA, Kamal MA.
CNS Neurol Disord Drug Targets. 2014;13(8):1432-9. Review.
A synopsis on the role of tyrosine hydroxylase in Parkinson's disease.
Tabrez S, Jabir NR, Shakil S, Greig NH, Alam Q, Abuzenadah AM, Damanhouri GA, Kamal MA.
CNS Neurol Disord Drug Targets. 2012 Jun 1;11(4):395-409. Review.
Alzheimer's disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylase.
Priyadarshini M, Kamal MA, Greig NH, Reale M, Abuzenadah AM, Chaudhary AG, Damanhouri GA.
CNS Neurol Disord Drug Targets. 2012 Jun 1;11(4):482-9. Review.
Interaction of human brain acetylcholinesterase with cyclophosphamide: a molecular modeling and docking study.
Shakil S, Khan R, Tabrez S, Alam Q, Jabir NR, Sulaiman MI, Greig NH, Kamal MA.
CNS Neurol Disord Drug Targets. 2011 Nov;10(7):845-8.
Inhibition of Butyrylcholinesterase with Fluorobenzylcymserine, An Experimental Alzheimer's Drug Candidate: Validation of Enzoinformatics Results by Classical and Innovative Enzyme Kinetic Analyses.
Kamal MA, Shakil S, Nawaz MS, Yu QS, Tweedie D, Tan Y, Qu X, Greig NH.
CNS Neurol Disord Drug Targets. 2017;16(7):820-827. doi: 10.2174/1871527316666170207160606.
Current Update on Synopsis of miRNA Dysregulation in Neurological Disorders.
Kamal MA, Mushtaq G, Greig NH.
CNS Neurol Disord Drug Targets. 2015;14(4):492-501. Review.
Quinoline derivatives: candidate drugs for a class B G-protein coupled receptor, the calcitonin gene-related peptide receptor, a cause of migraines.
Iftikhar H, Ahmad I, Gan SH, Shaik MM, Iftikhar N, Nawaz MS, Greig NH, Kamal MA.
CNS Neurol Disord Drug Targets. 2014;13(7):1130-9.
Molecular docking study of catecholamines and [4-(propan-2-yl) phenyl]carbamic acid with tyrosine hydroxylase.
Parveen Z, Nawaz MS, Shakil S, Greig NH, Kamal MA.
CNS Neurol Disord Drug Targets. 2012 Jun 1;11(4):463-8.
Editorial: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Development.
Kamal MA, Greig NH.
Curr Pharm Des. 2016;22(5):515-7. No abstract available.
Exploring N(1)-p-fluorobenzyl-cymserine as an inhibitor of 5-lipoxygenase as a candidate for type 2 diabetes and neurodegenerative disorder treatment.
ul Ain Q, Greig NH, Nawaz MS, Rashid S, Kamal MA.
CNS Neurol Disord Drug Targets. 2014 Mar;13(2):197-202.
Editorial: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Development (Part B).
Curr Pharm Des. 2016;22(20):2923-5. No abstract available.
Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Development (Part C)).
Curr Pharm Des. 2016;22(28):4337-40. No abstract available.
Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine.
Kamal MA, Al-Jafari AA, Yu QS, Greig NH.
Biochim Biophys Acta. 2006 Feb;1760(2):200-6. Epub 2005 Oct 27.
A Bayesian Model for the Prediction and Early Diagnosis of Alzheimer's Disease.
Alexiou A, Mantzavinos VD, Greig NH, Kamal MA.
Front Aging Neurosci. 2017 Mar 31;9:77. doi: 10.3389/fnagi.2017.00077. eCollection 2017.
Kinetics of human acetylcholinesterase inhibition by the novel experimental Alzheimer therapeutic agent, tolserine.
Kamal MA, Greig NH, Alhomida AS, Al-Jafari AA.
Biochem Pharmacol. 2000 Aug 15;60(4):561-70.
Peripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseases.
Reale M, Greig NH, Kamal MA.
Mini Rev Med Chem. 2009 Sep;9(10):1229-41. Review.
Neuronal cellular responses to extremely low frequency electromagnetic field exposure: implications regarding oxidative stress and neurodegeneration.
Reale M, Kamal MA, Patruno A, Costantini E, D'Angelo C, Pesce M, Greig NH.
PLoS One. 2014 Aug 15;9(8):e104973. doi: 10.1371/journal.pone.0104973. eCollection 2014.
Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective.
Ahmad J, Akhter S, Greig NH, Kamal MA, Midoux P, Pichon C.
Curr Pharm Des. 2016;22(28):4360-4373. Review.
Filters: Manage Filters